ACRV Adam D. Levy bought Acrivon Therapeutics, Inc. shares — SEC Form 4BUYAcrivon Therapeutics, Inc.

Adam D. Levy, Chief Financial Officer at Acrivon Therapeutics, Inc. (ACRV), bought 8,832 shares at $1.70 ($15K) on 2026-01-14, disclosed to the SEC on 2026-01-16.

SEC EDGAR Filing

0000905148-26-000225

View on SEC EDGAR

Why this matters (generating…)

High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.

Strong73/100

Clearly above the average filing.

Buying the DipMajor Holdings Increase (>50%)Opportunistic BuyFirst-Time BuyerDeep Dip Buy

Filing Info

Filed2026-01-16

Traded2026-01-14

Accession0000905148-26-000225

Sourcesec_form345

Insider

NameAdam D. Levy

TitleChief Financial Officer

PIT GradeInsiderUnrated

View Company View Insider

Related Trades by This Insider

Ticker	Type	Filed	Value	7d Stock	Filing
ACRV	SELL	2026-08-06	$2K	—	Filing →

Get an email when an insider at ACRV files

Free account. Follow ACRV and up to 10 more companies.

Follow ACRV for free

ACRV Adam D. Levy bought Acrivon Therapeutics, Inc. shares — SEC Form 4BUYAcrivon Therapeutics, Inc.

Filing Info

Insider

Related Trades by This Insider

Trade Details

Outcomes